Investment Thesis
Jupiter Neurosciences exhibits critical financial distress with negative stockholders' equity of -$1.8M, negligible revenue of $21.8K, and massive operating losses of -$8.9M. Annual cash burn of $5.4M against $3.8M in cash reserves indicates less than 12 months of runway, with deteriorating losses accelerating year-over-year, signaling imminent solvency risk.
Strengths
- Cash position of $3.8M provides short-term operational runway
- High gross margin of 80.6% demonstrates operational efficiency on generated revenue
- Pharmaceutical sector exposure offers potential for significant upside if development candidates succeed
Risks
- Negative stockholders' equity of -$1.8M indicates technical insolvency and liquidation risk
- Accelerating losses with net income deteriorating 254.4% year-over-year
- Severe cash burn of $5.4M annually with less than 12 months of runway before depletion
- Current ratio of 0.65x and working capital deficit indicate acute liquidity crisis
- Negligible revenue generation with no evidence of near-term path to commercialization
Key Metrics to Watch
- Monthly cash burn rate and total months of runway until capital exhaustion
- Progress on pipeline candidates and clinical trial milestones toward revenue generation
- Equity financing activities, dilution rate, and ability to extend runway
Financial Metrics
Revenue
21.8K
Net Income
-8.6M
EPS (Diluted)
$-0.25
Free Cash Flow
-5.4M
Total Assets
5.6M
Cash
3.8M
Profitability Ratios
Gross Margin
80.6%
Operating Margin
-40,873.2%
Net Margin
-39,662.8%
ROE
N/A
ROA
-155.4%
FCF Margin
-24,838.2%
Balance Sheet & Liquidity
Current Ratio
0.65x
Quick Ratio
0.63x
Debt/Equity
N/A
Debt/Assets
132.9%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-11T23:06:21.842435 |
Data as of: 2025-12-31 |
Powered by Claude AI